NSAID Use May Increase Death Risk in Endometrial Carcinoma Patients

A new study determined that nonsteroidal anti-inflammatory drugs (NSAID) were associated with a 66% increase of endometrial carcinoma-specific mortality, particularly in participants with type I cancers.

Researchers used data from 4374 participants from the NRG Oncology/Gynecology Oncology Group 210 Study with endometrial carcinoma that completed a pre-surgical questionnaire assessing the patient’s history of regular prediagnostic NSAID use and endometrial cancer risk factors. Medical records and cancer registries were used to obtain recurrences, vital status, and causes of death of participants. Models calculating the associations of NSAID use with endometrial carcinoma-specific mortality were stratified by type of cancer (I or II) and histology of patients.
Could Long-Term NSAID Use Cause Hearing Loss?
Certain NSAIDs May Increase Risk of Heart Attack, Stroke in Women

he analysis showed that 550 endometrial carcinoma-specific deaths and 737 recurrences occurred in follow-ups, with a median of 5 years. Women with type I cancer had a 66% increase in endometrial carcinoma-specific mortality, while type II did not show associations between endometrial carcinoma-related deaths and NSAID use.The participants who used NSAID for 10 years or longer with type I tumors showed the highest correlation between NSAID use and endometrial carcinoma-specific deaths.

“In this study, use of NSAIDs was associated with increased endometrial carcinoma-specific mortality, especially in patients with type I tumors. Barring a clear biologic mechanism by which NSAIDs would increase the risk of cause-specific mortality, cautious interpretation is warranted,” the researchers concluded. 

—Melissa Weiss


Brasky TM, Felix AS, Cohn DE, et al. Nonsteroidal anti-inflammatory drugs and endometrial carcinoma mortality and recurrence [published online December 16, 2016]. Journal of the National Cancer Institute. doi:10.1093/jnci/djw251.